Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …

Introduction Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is
approved in the United States and Europe for patients with relapsed/refractory multiple …

High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple
myeloma (NDMM), and dedicated studies should address this difficult-to-treat population …

Background CASSIOPEIA part 1 demonstrated superior depth of response and prolonged
progression-free survival with daratumumab in combination with bortezomib, thalidomide …

We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K),
lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in …

The prognostic impact of additional copies of chromosome 1q (1q+) on outcomes of newly-
diagnosed multiple myeloma (NDMM) patients undergoing autologous transplantation …

In the MASTER study (NCT03224507), daratumumab+ carfilzomib/lenalidomide/
dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly …

Melphalan, has been a major component of myeloma therapy since the 1950s. In the context
of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most …

Autologous stem cell transplantation (autoHCT) is considered standard of care for newly
diagnosed multiple myeloma (MM). Although most patients eventually progress after …